Laboratory Corp of America Holdings (LH)

Sector:
HEALTH CARE
Industry:
HEALTH CARE SERVICES
SIC:
SERVICES-MEDICAL LABORATORIES
CEO:
Adam H. Schechter
Employees:
75,200
358 S MAIN ST, BURLINGTON, NC 27215
3362291127

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, and prostate-specific antigens. The company also provides specialty testing services, including gene-based and esoteric testing.

Data derived from most recent annual or quarterly report
Market Cap 19.018 Billion Shares Outstanding88.6 Million Avg 30-day Volume 631.48 Thousand
P/E Ratio16.2636 Dividend Yield0.92 EPS3.91
Price to Revenue1.3983 Debt to Equity0.5263 EBITDA2.689 Billion
Price to Book Value2.0249 Operating Margin11.9239 Enterprise Value24.708 Billion
Current Ratio1.915 EPS Growth0 Quick Ratio1.599
1 Yr BETA 0.7754 52-week High/Low 277.5 / 199.15 Profit Margin8.608
Operating Cash Flow Growth45.6282 Altman Z-Score3.1178 Free Cash Flow to Firm 1.116 Billion
Earnings Report2023-05-04
View SEC Filings from LH instead.

View recent insider trading info

Laboratory Corp of America Holdings YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding LH (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LH

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-03-06 by SUMMY AMY B.
  • 4: filed on 2023-02-23 by KIRCHGRABER PAUL R
  • 4: filed on 2023-02-16 by SCHROEDER MARK S
  • 4: filed on 2023-02-14 by BELINGARD JEAN-LUC
  • 4: filed on 2023-02-14 by ANDERSON KERRII B
  • 4: filed on 2023-02-14 by DAVIS JEFFREY A.
  • 4: filed on 2023-02-14 by GILLILAND DWIGHT GARY
  • 4: filed on 2023-02-14 by KONG GARHENG
  • 4: filed on 2023-02-14 by NEUPERT PETER M
  • 4: filed on 2023-02-14 by PARHAM RICHELLE P

    • Events (8k)

  • 8-K: filed on 2023-02-16:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-18:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-12:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-05:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-03:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-31:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-27:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-12:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-03:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    9.4 Thousand total shares from 6 transactions

    Exercise Derivative Conversion (M)

    30.3 Thousand total shares from 41 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SUMMY AMY B. EVP, CHIEF MARKETING OFFICER

    • Officer
    		 1,669 2023-03-02 5

    KIRCHGRABER PAUL R CEO, COVANCE DRUG DEVELOPMENT

    • Officer
    		 9,069 2023-02-21 7

    SCHROEDER MARK S EVP, PRESIDENT-DIAGNOSTICS LAB

    • Officer
    		 6,687 2023-02-14 9

    BERBERIAN LANCE EVP, CIO & CTO

    • Officer
    		 20,168 2023-02-11 5

    BELINGARD JEAN-LUC

    • Director
    		 16,929 2023-02-11 2

    EISENBERG GLENN A CHIEF FINANCIAL OFFICER, EVP

    • Officer
    		 35,640 2023-02-11 8

    ANDERSON KERRII B

    • Director
    		 20,419 2023-02-11 2

    NEUPERT PETER M

    • Director
    		 10,996 2023-02-11 2

    WILLIAMS R SANDERS

    • Director
    		 7,173 2023-02-11 3

    SCHECHTER ADAM H PRESIDENT & CEO

    • Officer
    • Director
    		 23,181 2023-02-11 5

    WILKINSON PETER J SVP, CHIEF ACCOUNTING OFFICER

    • Officer
    		 2,160 2023-02-11 6

    KONG GARHENG

    • Director
    		 10,951 2023-02-11 2

    VAN DER VAART SANDRA D EVP, CHIEF LEGAL OFFICER

    • Officer
    		 5,553 2023-02-11 6

    PARHAM RICHELLE P

    • Director
    		 7,587 2023-02-11 2

    GILLILAND DWIGHT GARY

    • Director
    		 7,765 2023-02-11 2

    DAVIS JEFFREY A.

    • Director
    		 2,672 2023-02-11 2

    CAVENEY BRIAN J EVP, PRESIDENT OF DIAGNOSTICS

    • Officer
    		 16,413 2023-02-11 8

    WENGEL KATHRYN E

    • Director
    		 1,345 2023-02-11 3

    SELTZ JUDITH C EVP, CHRO

    • Officer
    		 1,965 2023-02-11 4

    KLIPHOUSE KIRSTEN MARIE

    • Director
    		 0 2023-02-07 3

    PIKE THOMAS PRES & CEO CLINICAL BUSINESS

    • Officer
    		 0 2023-01-09 2

    KING DAVID P

    • Director
    		 332,096 2020-05-05 0

    UTHGENANNT LISA J CHIEF HUMAN RESOURCES OFFICER

    • Officer
    		 4,660 2019-09-04 0

    MITTELSTAEDT ROBERT E JR

    • Director
    		 No longer subject to file 2019-05-09 0

    RATLIFF JOHN D CEO, COVANCE DRUG DEVELOPMENT

    • Officer
    		 17,061 2019-04-03 0

    DODSON EDWARD T PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 No longer subject to file 2019-04-01 0

    EBERTS F SAMUEL III CHIEF LEGAL OFFICER, SECRETARY

    • Officer
    		 28,823 2019-02-12 0

    GARY M. HUFF CEO, LABCORP DIAGNOSTICS

    • Officer
    		 1,850 2018-09-04 0

    BOYLE JAMES T. JR. EVP,CEO OF LABCORP DIAGNOSTICS

    • Officer
    		 23,454 2016-03-30 0

    KELLER DEBORAH L CEO, COVANCE DRUG DEVELOPMENT

    • Officer
    		 19,754 2016-03-11 0

    HERRING JOSEPH L CEO OF COVANCE DRUG DIVISION

    • Officer
    		 No longer subject to file 2015-07-31 0

    BRECHER MARK E CMO, LABCORP DIAGNOSTICS

    • Officer
    		 5,511 2015-03-30 0

    HAYES WILLIAM B CHIEF FINANCIAL OFFICER, EVP

    • Officer
    		 19,400 2014-06-06 0

    LANE WENDY E

    • Director
    		 19,388 2014-05-08 0

    RUBENSTEIN ARTHUR H

    • Director
    		 11,772 2014-05-08 0

    WEIKEL M KEITH

    • Director
    		 13,958 2014-05-07 0

    FONSECA LIDIA CHIEF INFORMATION OFFICER

    • Officer
    		 9,087 2013-03-28 0

    COLES N ANTHONY

    • Director
    		 2,584 2013-02-15 0

    MAC MAHON THOMAS P

    • Director
    		 32,297 2012-09-06 0

    WALTON ANDREW SCOTT EVP

    • Officer
    		 22,298 2012-04-09 0

    CONRAD ANDREW J EVP, CHIEF SCIENTIFIC OFFICER

    • Officer
    		 32,641 2011-02-09 0

    HARDISON DON M EVP

    • Officer
    		 19,928 2009-12-31 0

    SMITH BRADFORD T

    • Director
    		 16,030 2009-02-20 0

    LAI GOLDMAN MYLA EVP & CHIEF MEDICAL OFFICER

    • Officer
    		 24,991 2008-11-20 0

    HAAS WILLIAM EVP, ESOTERIX BUSINESS

    • Officer
    		 0 2008-05-07 0

    MILLER BENJAMIN R EVP, SALES & MARKETING

    • Officer
    		 10,135 2008-03-06 0

    COOK WOODROW L EVP, EASTERN OPERATIONS

    • Officer
    		 12,535 2007-10-30 0

    WALLACE ANDREW G

    • Director
    		 11,654 2007-05-01 0

    TROUB ALLEN W EVP, WESTERN OPERATIONS

    • Officer
    		 12,960 2007-02-23 0

    NOVAK RICHARD L EVP & STRATEGIC PLANNING

    • Officer
    		 64,806 2006-03-01 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-03-06 08:04:10 -0500 2023-03-02 F 374 $239.46 d 1,669 direct -2.3618 -7.5324 0.0 1 -7.5324 6

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-03-06 08:04:10 -0500 2023-03-02 M 1,340 a 2,043 direct -2.3618 -7.5324 0.0 1 -7.5324 6

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-03-06 08:04:10 -0500 2023-03-02 M 1,340 d 1,180 direct

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-23 09:54:27 -0500 2023-02-21 M 3,000 $182.51 a 17,069 direct -1.102 -2.2612 0.0 1 -2.9061 5

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-23 09:54:27 -0500 2023-02-21 M 3,000 d 4,300 direct

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-23 09:54:27 -0500 2023-02-21 S 8,000 $250.58 d 9,069 direct -1.102 -2.2612 0.0 1 -2.9061 5

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-16 12:51:06 -0500 2023-02-14 S 309 $247.63 d 6,687 direct yes 0.0664 -5.1084 0.0666 2 -5.1084 6

    CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

    		2023-02-14 14:59:04 -0500 2023-02-13 F 124 $248.13 d 16,413 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-14 14:57:47 -0500 2023-02-13 F 142 $248.13 d 14,069 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

    		2023-02-14 14:56:30 -0500 2023-02-13 F 195 $248.13 d 35,640 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

    		2023-02-14 14:55:31 -0500 2023-02-13 F 1,170 $248.13 d 23,181 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-14 14:54:11 -0500 2023-02-13 F 114 $248.13 d 6,996 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    SELTZ JUDITH C - Officer EVP, CHRO

    		2023-02-14 14:52:58 -0500 2023-02-13 F 69 $248.13 d 1,965 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-02-14 14:51:55 -0500 2023-02-13 F 54 $248.13 d 703 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-14 14:50:49 -0500 2023-02-13 F 78 $248.13 d 5,553 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

    		2023-02-14 14:49:27 -0500 2023-02-13 F 38 $248.13 d 2,160 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    BERBERIAN LANCE - Officer EVP, CIO & CTO

    		2023-02-14 15:01:56 -0500 2023-02-13 F 85 $248.13 d 20,168 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    BELINGARD JEAN-LUC - Director

    		2023-02-14 15:25:14 -0500 2023-02-13 F 75 $248.13 d 16,929 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

    		2023-02-14 14:59:04 -0500 2023-02-11 M 423 a 16,537 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

    		2023-02-14 14:59:04 -0500 2023-02-11 M 423 d 2,681 direct

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-14 14:57:47 -0500 2023-02-11 M 483 a 14,211 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-14 14:57:47 -0500 2023-02-11 M 483 d 3,001 direct

    EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

    		2023-02-14 14:56:30 -0500 2023-02-11 M 723 a 35,835 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

    		2023-02-14 14:56:30 -0500 2023-02-11 M 723 d 13,764 direct

    SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

    		2023-02-14 14:55:31 -0500 2023-02-11 M 2,656 a 24,351 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

    		2023-02-14 14:55:31 -0500 2023-02-11 M 2,656 d 16,828 direct

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-14 14:54:11 -0500 2023-02-11 M 423 a 7,110 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-14 14:54:11 -0500 2023-02-11 M 423 d 2,681 direct

    SELTZ JUDITH C - Officer EVP, CHRO

    		2023-02-14 14:52:58 -0500 2023-02-11 M 236 a 2,034 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    SELTZ JUDITH C - Officer EVP, CHRO

    		2023-02-14 14:52:58 -0500 2023-02-11 M 236 d 1,464 direct

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-02-14 14:51:55 -0500 2023-02-11 M 180 a 757 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-02-14 14:51:55 -0500 2023-02-11 M 180 d 2,520 direct

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-14 14:50:49 -0500 2023-02-11 M 290 a 5,631 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-14 14:50:49 -0500 2023-02-11 M 290 d 1,767 direct

    WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

    		2023-02-14 14:49:27 -0500 2023-02-11 M 110 a 2,198 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

    		2023-02-14 14:49:27 -0500 2023-02-11 M 110 d 747 direct

    WILLIAMS R SANDERS - Director

    		2023-02-14 15:07:27 -0500 2023-02-11 M 742 a 7,173 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    WILLIAMS R SANDERS - Director

    		2023-02-14 15:07:27 -0500 2023-02-11 M 742 d 849 direct

    WENGEL KATHRYN E - Director

    		2023-02-14 15:11:43 -0500 2023-02-11 M 742 a 1,345 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    WENGEL KATHRYN E - Director

    		2023-02-14 15:11:43 -0500 2023-02-11 M 742 d 849 direct

    GILLILAND DWIGHT GARY - Director

    		2023-02-14 15:16:32 -0500 2023-02-11 M 742 a 7,765 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    GILLILAND DWIGHT GARY - Director

    		2023-02-14 15:16:32 -0500 2023-02-11 M 742 d 849 direct

    KONG GARHENG - Director

    		2023-02-14 15:15:24 -0500 2023-02-11 M 742 a 10,951 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    KONG GARHENG - Director

    		2023-02-14 15:15:24 -0500 2023-02-11 M 742 d 849 direct

    NEUPERT PETER M - Director

    		2023-02-14 15:14:15 -0500 2023-02-11 M 742 a 10,996 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    NEUPERT PETER M - Director

    		2023-02-14 15:14:15 -0500 2023-02-11 M 742 d 849 direct

    PARHAM RICHELLE P - Director

    		2023-02-14 15:13:14 -0500 2023-02-11 M 742 a 7,587 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    PARHAM RICHELLE P - Director

    		2023-02-14 15:13:14 -0500 2023-02-11 M 742 d 849 direct

    BERBERIAN LANCE - Officer EVP, CIO & CTO

    		2023-02-14 15:01:56 -0500 2023-02-11 M 290 a 20,253 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    BERBERIAN LANCE - Officer EVP, CIO & CTO

    		2023-02-14 15:01:56 -0500 2023-02-11 M 290 d 1,827 direct

    ANDERSON KERRII B - Director

    		2023-02-14 15:22:24 -0500 2023-02-11 M 742 a 20,275 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    ANDERSON KERRII B - Director

    		2023-02-14 15:22:24 -0500 2023-02-11 M 742 d 849 direct

    BELINGARD JEAN-LUC - Director

    		2023-02-14 15:25:14 -0500 2023-02-11 M 742 a 17,004 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    BELINGARD JEAN-LUC - Director

    		2023-02-14 15:25:14 -0500 2023-02-11 M 742 d 849 direct

    DAVIS JEFFREY A. - Director

    		2023-02-14 15:17:39 -0500 2023-02-11 M 742 a 2,672 direct 1.7919 -0.3167 5.0806 4 -0.3167 6

    DAVIS JEFFREY A. - Director

    		2023-02-14 15:17:39 -0500 2023-02-11 M 742 d 849 direct

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-02-09 09:03:13 -0500 2023-02-07 A 600 a 2,700 direct

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-02-09 09:03:13 -0500 2023-02-07 A 1,900 a 1,900 direct

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-09 09:04:51 -0500 2023-02-07 S 409 $243.01 d 6,687 direct yes 1.023 5.2136 5.2136 6 0.0 1

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-09 09:04:51 -0500 2023-02-07 A 1,390 a 3,104 direct

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-09 09:04:51 -0500 2023-02-07 A 4,400 a 4,400 direct

    SELTZ JUDITH C - Officer EVP, CHRO

    		2023-02-09 09:23:10 -0500 2023-02-07 A 770 a 1,700 direct

    SELTZ JUDITH C - Officer EVP, CHRO

    		2023-02-09 09:23:10 -0500 2023-02-07 A 2,400 a 2,400 direct

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-09 09:27:17 -0500 2023-02-07 S 219 $243.01 d 5,341 direct yes 1.023 5.2136 5.2136 6 0.0 1

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-09 09:27:17 -0500 2023-02-07 A 950 a 2,057 direct

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-09 09:27:17 -0500 2023-02-07 A 3,000 a 3,000 direct

    EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

    		2023-02-09 09:28:23 -0500 2023-02-07 A 2,380 a 14,487 direct

    EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

    		2023-02-09 09:28:23 -0500 2023-02-07 A 7,500 a 7,500 direct

    CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

    		2023-02-09 09:29:26 -0500 2023-02-07 A 1,390 a 3,104 direct

    CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

    		2023-02-09 09:29:26 -0500 2023-02-07 A 4,400 a 4,400 direct

    BERBERIAN LANCE - Officer EVP, CIO & CTO

    		2023-02-09 09:31:40 -0500 2023-02-07 A 950 a 2,117 direct

    BERBERIAN LANCE - Officer EVP, CIO & CTO

    		2023-02-09 09:31:40 -0500 2023-02-07 A 3,000 a 3,000 direct

    SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

    		2023-02-09 09:33:31 -0500 2023-02-07 A 8,740 a 19,484 direct

    SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

    		2023-02-09 09:33:31 -0500 2023-02-07 A 27,400 a 27,400 direct

    BELINGARD JEAN-LUC - Director

    		2023-02-09 12:07:39 -0500 2023-02-07 A 849 a 1,591 direct

    PARHAM RICHELLE P - Director

    		2023-02-09 12:06:20 -0500 2023-02-07 A 849 a 1,591 direct

    DAVIS JEFFREY A. - Director

    		2023-02-09 12:11:19 -0500 2023-02-07 A 849 a 1,591 direct

    ANDERSON KERRII B - Director

    		2023-02-09 12:10:01 -0500 2023-02-07 A 849 a 1,591 direct

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-09 12:02:35 -0500 2023-02-07 A 1,590 a 3,484 direct

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-09 12:02:35 -0500 2023-02-07 A 5,000 a 5,000 direct

    GILLILAND DWIGHT GARY - Director

    		2023-02-09 12:13:01 -0500 2023-02-07 A 849 a 1,591 direct

    WILLIAMS R SANDERS - Director

    		2023-02-09 12:20:21 -0500 2023-02-07 A 849 a 1,591 direct

    WENGEL KATHRYN E - Director

    		2023-02-09 12:24:12 -0500 2023-02-07 A 849 a 1,591 direct

    NEUPERT PETER M - Director

    		2023-02-09 12:26:19 -0500 2023-02-07 A 849 a 1,591 direct

    KLIPHOUSE KIRSTEN MARIE - Director

    		2023-02-09 12:25:26 -0500 2023-02-07 A 849 a 1,182 direct

    KONG GARHENG - Director

    		2023-02-09 12:34:02 -0500 2023-02-07 A 849 a 1,591 direct

    WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

    		2023-02-09 12:43:09 -0500 2023-02-07 A 360 a 857 direct

    WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

    		2023-02-09 12:43:09 -0500 2023-02-07 A 1,100 a 1,100 direct

    WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

    		2023-02-07 14:45:50 -0500 2023-02-06 F 52 $244.50 d 2,088 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-07 14:47:03 -0500 2023-02-06 F 81 $244.50 d 5,560 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SELTZ JUDITH C - Officer EVP, CHRO

    		2023-02-07 14:48:57 -0500 2023-02-06 F 84 $244.50 d 1,798 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-02-07 14:47:53 -0500 2023-02-06 F 83 $244.50 d 577 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-07 14:50:16 -0500 2023-02-06 F 151 $244.50 d 7,096 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

    		2023-02-07 14:52:33 -0500 2023-02-06 F 261 $244.50 d 35,112 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-07 14:51:34 -0500 2023-02-06 F 164 $244.50 d 13,728 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    BERBERIAN LANCE - Officer EVP, CIO & CTO

    		2023-02-07 14:53:33 -0500 2023-02-06 F 108 $244.50 d 19,963 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

    		2023-02-07 14:55:46 -0500 2023-02-06 F 1,368 $244.50 d 21,695 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

    		2023-02-07 14:54:38 -0500 2023-02-06 F 164 $244.50 d 16,114 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

    		2023-02-07 14:45:50 -0500 2023-02-04 M 150 a 2,140 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

    		2023-02-07 14:45:50 -0500 2023-02-04 M 150 d 497 direct

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-07 14:47:03 -0500 2023-02-04 M 300 a 5,641 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-07 14:47:03 -0500 2023-02-04 M 300 d 1,107 direct

    SELTZ JUDITH C - Officer EVP, CHRO

    		2023-02-07 14:48:57 -0500 2023-02-04 M 280 a 1,882 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SELTZ JUDITH C - Officer EVP, CHRO

    		2023-02-07 14:48:57 -0500 2023-02-04 M 280 d 930 direct

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-02-07 14:47:53 -0500 2023-02-04 M 267 a 660 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-02-07 14:47:53 -0500 2023-02-04 M 267 d 2,100 direct

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-07 14:50:16 -0500 2023-02-04 M 560 a 7,247 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-07 14:50:16 -0500 2023-02-04 M 560 d 1,714 direct

    EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

    		2023-02-07 14:52:33 -0500 2023-02-04 M 970 a 35,373 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

    		2023-02-07 14:52:33 -0500 2023-02-04 M 970 d 12,107 direct

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-07 14:51:34 -0500 2023-02-04 M 560 a 13,892 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-07 14:51:34 -0500 2023-02-04 M 560 d 1,894 direct

    BERBERIAN LANCE - Officer EVP, CIO & CTO

    		2023-02-07 14:53:33 -0500 2023-02-04 M 374 a 20,071 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    BERBERIAN LANCE - Officer EVP, CIO & CTO

    		2023-02-07 14:53:33 -0500 2023-02-04 M 374 d 1,167 direct

    SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

    		2023-02-07 14:55:46 -0500 2023-02-04 M 3,507 a 23,063 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

    		2023-02-07 14:55:46 -0500 2023-02-04 M 3,507 d 10,744 direct

    CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

    		2023-02-07 14:54:38 -0500 2023-02-04 M 560 a 16,278 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

    		2023-02-07 14:54:38 -0500 2023-02-04 M 560 d 1,714 direct

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-06 15:51:51 -0500 2023-02-03 S 324 $253.90 d 6,687 direct yes -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-06 15:56:46 -0500 2023-02-03 S 173 $253.90 d 5,341 direct yes -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

    		2023-02-06 15:41:37 -0500 2023-02-02 F 144 $254.99 d 15,718 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

    		2023-02-06 15:41:37 -0500 2023-02-02 M 443 a 15,862 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    CAVENEY BRIAN J - Officer EVP, PRESIDENT OF DIAGNOSTICS

    		2023-02-06 15:41:37 -0500 2023-02-02 M 443 d 2,274 direct

    BERBERIAN LANCE - Officer EVP, CIO & CTO

    		2023-02-06 15:40:29 -0500 2023-02-02 F 102 $254.99 d 19,697 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    BERBERIAN LANCE - Officer EVP, CIO & CTO

    		2023-02-06 15:40:29 -0500 2023-02-02 M 297 a 19,799 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    BERBERIAN LANCE - Officer EVP, CIO & CTO

    		2023-02-06 15:40:29 -0500 2023-02-02 M 297 d 1,541 direct

    EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

    		2023-02-06 15:43:35 -0500 2023-02-02 F 206 $254.99 d 34,403 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

    		2023-02-06 15:43:35 -0500 2023-02-02 M 767 a 34,609 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    EISENBERG GLENN A - Officer CHIEF FINANCIAL OFFICER, EVP

    		2023-02-06 15:43:35 -0500 2023-02-02 M 767 d 13,077 direct

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-06 15:45:49 -0500 2023-02-02 F 141 $254.99 d 13,332 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-06 15:45:49 -0500 2023-02-02 M 443 a 13,473 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    KIRCHGRABER PAUL R - Officer CEO, COVANCE DRUG DEVELOPMENT

    		2023-02-06 15:45:49 -0500 2023-02-02 M 443 d 2,454 direct

    SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

    		2023-02-06 15:49:49 -0500 2023-02-02 F 805 $254.99 d 19,556 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

    		2023-02-06 15:49:49 -0500 2023-02-02 M 2,773 a 20,361 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SCHECHTER ADAM H - Director - Officer PRESIDENT & CEO

    		2023-02-06 15:49:49 -0500 2023-02-02 M 2,773 d 14,251 direct

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-06 15:51:51 -0500 2023-02-02 F 119 $254.99 d 7,011 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-06 15:51:51 -0500 2023-02-02 M 443 a 7,130 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SCHROEDER MARK S - Officer EVP, PRESIDENT-DIAGNOSTICS LAB

    		2023-02-06 15:51:51 -0500 2023-02-02 M 443 d 2,274 direct

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-02-06 15:54:38 -0500 2023-02-02 F 77 $254.99 d 393 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-02-06 15:54:38 -0500 2023-02-02 M 220 a 470 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SUMMY AMY B. - Officer EVP, CHIEF MARKETING OFFICER

    		2023-02-06 15:54:38 -0500 2023-02-02 M 220 d 2,367 direct

    WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

    		2023-02-06 15:55:39 -0500 2023-02-02 F 41 $254.99 d 1,990 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

    		2023-02-06 15:55:39 -0500 2023-02-02 M 117 a 2,031 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    WILKINSON PETER J - Officer SVP, CHIEF ACCOUNTING OFFICER

    		2023-02-06 15:55:39 -0500 2023-02-02 M 117 d 647 direct

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-06 15:56:46 -0500 2023-02-02 F 64 $254.99 d 5,514 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-06 15:56:46 -0500 2023-02-02 M 237 a 5,578 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    VAN DER VAART SANDRA D - Officer EVP, CHIEF LEGAL OFFICER

    		2023-02-06 15:56:46 -0500 2023-02-02 M 237 d 1,407 direct

    SELTZ JUDITH C - Officer EVP, CHRO

    		2023-02-06 16:00:14 -0500 2023-02-02 F 77 $254.99 d 1,602 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SELTZ JUDITH C - Officer EVP, CHRO

    		2023-02-06 16:00:14 -0500 2023-02-02 M 220 a 1,679 direct -0.5177 -1.363 -11.9787 3.6484 9 -13.4675 28

    SELTZ JUDITH C - Officer EVP, CHRO

    		2023-02-06 16:00:14 -0500 2023-02-02 M 220 d 1,210 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    LABORATORY CRP OF AMER HLDGS LH 2023-03-24 15:15:03 UTC 4.57 0.25 2600000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-24 14:45:03 UTC 4.57 0.25 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-24 14:15:03 UTC 4.57 0.25 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-24 13:45:03 UTC 4.3072 0.2628 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-24 13:15:04 UTC 4.3072 0.2628 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-24 12:45:03 UTC 4.3072 0.2628 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 22:15:04 UTC 4.3072 0.2628 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 21:45:04 UTC 4.3077 0.2623 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 21:15:04 UTC 4.3077 0.2623 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 20:45:03 UTC 4.3105 0.2595 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 20:15:03 UTC 4.3105 0.2595 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 19:45:03 UTC 4.3105 0.2595 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 19:15:03 UTC 4.3105 0.2595 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 18:45:04 UTC 4.3105 0.2595 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 18:15:03 UTC 4.3105 0.2595 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 17:45:03 UTC 4.3105 0.2595 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 17:15:03 UTC 4.3105 0.2595 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 16:45:04 UTC 4.2878 0.2822 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 16:15:03 UTC 4.2878 0.2822 2700000
    LABORATORY CRP OF AMER HLDGS LH 2023-03-23 15:45:03 UTC 4.2878 0.2822 2700000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Master Neutral Fund LH -12.0 shares, $-2259.24 2020-09-30 N-PORT
    GLENMEDE FUND INC- Alternative Risk Premia Portfolio LH -74.0 shares, $-12169.3 2020-04-30 N-PORT
    INVESTMENT MANAGERS SERIES TRUST- AAM HIMCO Global Enhanced Dividend Fund LH -832.0 shares, $-212184.96 2021-03-31 N-PORT
    AGF Investments Trust- AGFIQ Hedged Dividend Income Fund LH -27.0 shares, $-7118.82 2022-03-31 N-PORT
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund LH -11324.0 shares, $-2319268.44 2022-09-30 N-PORT
    Alger Funds II- Alger Dynamic Opportunities Fund LH -1785.0 shares, $-396020.1 2022-10-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund LH -800.0 shares, $-188384.0 2022-12-31 N-PORT
    First Trust Exchange-Traded Fund III- First Trust Long/Short Equity ETF LH -455.0 shares, $-114714.6 2023-01-31 N-PORT

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Rohit Khanna democrat House Filing 2023-03-01 2023-02-14 DC S $1,001-$15,000
    Hon. Rohit Khanna democrat House Filing 2023-02-02 2023-01-11 DC P $1,001-$15,000
    Hon. Rohit Khanna democrat House Filing 2022-12-02 2022-11-03 SP S $1,001-$15,000

    Elevate your investments